What is Leerink Partnrs’ Forecast for AXSM FY2027 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Research analysts at Leerink Partnrs lifted their FY2027 earnings estimates for shares of Axsome Therapeutics in a research report issued on Monday, November 3rd. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn $4.45 per share for the year, up from their previous estimate of $4.40. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ FY2028 earnings at $10.30 EPS and FY2029 earnings at $18.75 EPS.

Other equities research analysts also recently issued research reports about the stock. Bank of America lifted their target price on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Guggenheim raised their price target on Axsome Therapeutics from $200.00 to $205.00 and gave the stock a “buy” rating in a research note on Tuesday. Wells Fargo & Company lowered their target price on Axsome Therapeutics from $163.00 to $157.00 and set an “overweight” rating on the stock in a report on Tuesday. B. Riley began coverage on shares of Axsome Therapeutics in a research report on Wednesday, October 1st. They set a “buy” rating and a $179.00 price target for the company. Finally, Morgan Stanley upped their price target on shares of Axsome Therapeutics from $194.00 to $196.00 and gave the company an “overweight” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $180.75.

Axsome Therapeutics Stock Up 0.6%

AXSM opened at $135.69 on Wednesday. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. Axsome Therapeutics has a twelve month low of $75.56 and a twelve month high of $139.13. The stock has a market capitalization of $6.77 billion, a price-to-earnings ratio of -26.76 and a beta of 0.52. The firm has a 50 day moving average price of $124.02 and a 200-day moving average price of $113.19.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The company had revenue of $170.99 million for the quarter, compared to the consensus estimate of $162.96 million. The business’s quarterly revenue was up 63.2% on a year-over-year basis.

Hedge Funds Weigh In On Axsome Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Moors & Cabot Inc. lifted its holdings in Axsome Therapeutics by 4.5% during the second quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock valued at $243,000 after purchasing an additional 100 shares in the last quarter. Meridian Wealth Management LLC raised its position in shares of Axsome Therapeutics by 0.5% during the 3rd quarter. Meridian Wealth Management LLC now owns 22,124 shares of the company’s stock valued at $2,687,000 after purchasing an additional 103 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Axsome Therapeutics by 1.1% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock worth $1,032,000 after buying an additional 107 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in Axsome Therapeutics by 6.8% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 2,101 shares of the company’s stock worth $255,000 after buying an additional 134 shares in the last quarter. Finally, Mutual of America Capital Management LLC increased its stake in Axsome Therapeutics by 0.3% in the 1st quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company’s stock worth $4,621,000 after buying an additional 136 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Transactions at Axsome Therapeutics

In related news, CEO Herriot Tabuteau sold 21,775 shares of the business’s stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $134.49, for a total transaction of $2,928,519.75. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at approximately $972,228.21. The trade was a 75.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Mark L. Jacobson sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $115.96, for a total value of $1,159,600.00. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 407,271 shares of company stock valued at $50,640,415. Company insiders own 22.30% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.